Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn’s Disease

Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes

(2014) Mireia Lopez-Siles et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Implications of the human microbiome in inflammatory bowel diseases

(2013) Syeda M. Bakhtiar et al.   FEMS MICROBIOLOGY LETTERS

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

The gut microbiota in IBD

(2012) Chaysavanh Manichanh et al.   Nature Reviews Gastroenterology & Hepatology

New therapies for inflammatory bowel disease: from the bench to the bedside

(2011) Silvio Danese   GUT

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

(2010) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Innate Immunity in Crohnʼs Disease

(2010) Rodrigue Dessein et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Gut Microbiota in Health and Disease

(2010) Inna Sekirov et al.   PHYSIOLOGICAL REVIEWS

Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases

(2009) Christopher D Packey et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Molecular diversity of Escherichia coli in the human gut: New ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohnʼs disease

(2009) Margarita Martinez-Medina et al.   INFLAMMATORY BOWEL DISEASES

Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohnʼs disease

(2008) Ben Willing et al.   INFLAMMATORY BOWEL DISEASES